Evidence map›Paper›PMID 42153322›Full record

ReviewBriefings in bioinformatics2026

Foundation models and deep learning for cancer drug response prediction: a framework for data, metrics, and validation.

Katyna Sada Del Real, Vinay S Swamy, Josefina Arcagni, Eric Wang, Raul Rabadan, Angel Rubio

Abstract readReview
In one paragraph

Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katyna Sada Del RealDepartamento de Ingeniería Biomédica y Ciencias, TECNUN, Universidad de Navarra, Paseo de Manuel Lardizábal 13, 20018 San Sebastián, Gipuzkoa, Spain.ORCID 0000-0002-7634-7962
Vinay S SwamyDepartment of Biomedical Informatics, Columbia University, 622 West 168th Street, Washington Heights, New York, NY 10032, United States.
Josefina ArcagniDepartamento de Ingeniería Biomédica y Ciencias, TECNUN, Universidad de Navarra, Paseo de Manuel Lardizábal 13, 20018 San Sebastián, Gipuzkoa, Spain.ORCID 0009-0009-4146-5780
Eric WangGoogle DeepMind, 1600 Amphitheatre Parkway, North Bayshore, Mountain View, CA 94043, United States.
Raul RabadanGoogle DeepMind, 1600 Amphitheatre Parkway, North Bayshore, Mountain View, CA 94043, United States.ORCID 0000-0001-7946-9255
Angel RubioDepartamento de Ingeniería Biomédica y Ciencias, TECNUN, Universidad de Navarra, Paseo de Manuel Lardizábal 13, 20018 San Sebastián, Gipuzkoa, Spain.ORCID 0000-0002-3274-2450

Funding

Cancer Research UK C355/A26819
6 · The paper itself

Abstract

The emergence of large-scale omics data and foundational models has renewed efforts in the field of cancer drug response prediction (DRP). Despite recent progress, challenges such as limited tumor heterogeneity in standard cell lines and inconsistencies in experimental protocols across studies persist. However, these challenges also open significant opportunities for innovation. The complex nature of drug responses, influenced by variations in new patients and new drugs, presents a critical area for advancing validation approaches that traditional machine learning approaches often overlook. This review provides a comprehensive overview of the current state of DRP using advanced machine-learning models, discussing data sources, model designs, and evaluation methods. We introduce a unified framework for testing these models with a focus on clinically relevant metrics. By evaluating a range of foundational and deep-learning models within this framework, we identify performance gaps and propose concrete strategies to advance these computational models for reliable use in personalized cancer treatment, thereby unlocking their full clinical potential.

Indexed as

Antineoplastic AgentsDeep LearningNeoplasmsComputational BiologyHumansPrediction AlgorithmsPredictive Learning ModelsAntineoplastic Agentscancer drug responseframeworkmachine learningmetrics

Identifiers

PMID42153322
PMCPMC13184516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.